EP0846116A1 - Derives de 1-benzoyl-2-(indolyl-3-alkyl)-piperazine utilises comme antagonistes du recepteur de la neurokinine - Google Patents
Derives de 1-benzoyl-2-(indolyl-3-alkyl)-piperazine utilises comme antagonistes du recepteur de la neurokinineInfo
- Publication number
- EP0846116A1 EP0846116A1 EP96915200A EP96915200A EP0846116A1 EP 0846116 A1 EP0846116 A1 EP 0846116A1 EP 96915200 A EP96915200 A EP 96915200A EP 96915200 A EP96915200 A EP 96915200A EP 0846116 A1 EP0846116 A1 EP 0846116A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- compound
- salt
- alkyl
- formula
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Definitions
- the present invention relates to new piperazine derivatives and a pharmaceutically acceptable salt thereof.
- new piperazine derivatives and a pharmaceutically acceptable salt thereof which have pharmacological activities such as Tachykinin antagonism, especially Substance P antagonism, Neurokinin A antagonism, Neurokinin B antagonism, and the like, to a process for preparation thereof, to a pharmaceutical composition comprising the same, and to a use of the same as a medicament.
- one object of the present invention is to provide new and useful piperazine derivatives and a pharmaceutically acceptable salt thereof which have pharmacological activities such as Tachykinin antagonism, especially Substance P antagonism, Neurokinin A antagonism, Neurokinin B antagonism, and the like.
- Another object of the present invention is to provide a process for the preparation of said piperazine derivatives ⁇ and a salt thereof.
- a further object of the present invention is to provide a pharmaceutical composition comprising, as an active ingredient, said piperazine derivatives and a pharmaceutically acceptable salt thereof.
- Still further object of the present invention is to provide a use of said piperazine derivatives or a pharmaceutically acceptable salt thereof as Tachykinin antagonist, especially Substance P antagonist, Neurokinin A antagonist or Neurokinin B antagonist, useful for treating or preventing Tachykinin-mediated diseases, for example, respiratory diseases such as asthma, bronchitis, rhinitis, cough, expectoration, and the like; ophthalmic diseases such as conjunctivitis, vernal conjunctivitis, and the like; cutaneous diseases such as contact dermatitis, atopic dermatitis, urticaria, and other eczematoid dermatitis, and the like; inflammatory diseases such as rheumatoid arthritis, osteoarthritis, and the like; pains or aches (e.g., migraine, headache, toothache cancerous pain, back pain, etc.); and the like in human being or animals.
- respiratory diseases such as asthma, bronchitis, rhinitis, cough, expectoration
- the object compound of the present invention is the compound of the following formula (I) :
- the other object compound of the present invention can be represented by the following general formula (Ig) :
- R 1 is trihalo (lower)alkyl
- R ⁇ is trihalo (lower)alkyl
- R J is mdolyl(lower)alkyl
- -A- is -CH' or - -flC-*CH 2 - and
- R is hydrogen or lower alkoxycarbonyl
- R 6 is hydrogen or lower alkanoyl
- R 7 is hydrogen, lower alkyl, lower alkanoyl, lower alkoxycarbonyl, lower alkoxy(lower)alkanoyl, cyclo(lower)alkylcarbonyl, aroyl or lower alkylsulfonyl, or its pharmaceutically acceptable salt.
- the object compounds can be prepared by processes which are illustrated in the following schemes. - t -
- Suitable salts and pharmaceutically acceptable salts of the starting and object compounds are conventional non-toxic salt and include an acid addition salt such as an organic acid salt (e.g. acetate, trifluoroacetate, fumarate, maleate, tartrate, methanesulfonate, benzenesulfonate, formate, toluenesulfonate, etc.), an inorganic acid salt (e.g. hydrochloride, hydrobromide, hydroiodide, sulfate, nitrate, phosphate, etc.), or a salt with an amino acid (e.g. arginine, aspartic acid, glutamic acid, etc.), or a metal salt such as an alkali metal salt (e.g.
- an organic acid salt e.g. acetate, trifluoroacetate, fumarate, maleate, tartrate, methanesulfonate, benzenesulfonate, formate, toluenesulfonate
- an alkaline earth metal salt e.g. calcium salt, magnesium salt, etc.
- an ammonium salt e.g. sodium salt, potassium salt, etc.
- an organic base salt e.g. trimethylamine salt, triethylamine salt, pyridine salt, picoline salt, dicyclohexylamine salt, N,N'-dibenzylethylenediamine salt, etc.
- an organic base salt e.g. trimethylamine salt, triethylamine salt, pyridine salt, picoline salt, dicyclohexylamine salt, N,N'-dibenzylethylenediamine salt, etc.
- Suitable "lower alkyl” and “lower alkyl moiety" in the terms “indolyl(lower)alkyl” and “lower alkylsulfonyl” is straight or branched one having 1 to 6 carbon atom(s) and may include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, pentyl, hexyl and the like.
- Suitable “trihalo (lower) alkyl” may include trichloromethyl, tribromomethyl, trifluoromethyl and the like.
- Suitable "lower alkoxy” and “lower alkoxy moiety" in the terms “lower alkoxycarbonyl” and “lower alkoxy(lower)alkanoyl” may include methoxy, ethoxy, isopropyloxy, butoxy and the like.
- Suitable "lower alkanoyl” and “lower alkanoyl moiety" in the term “lower alkoxy(lower)alkanoyl” may include formyl, acetyl, propionyl, butyryl, isobutyryl, valeryl, hexanoyl, pivaloyl and the like.
- Suitable "cyclo (lower)alkyl moiety" in the term “cyclo(lower) alkylcarbonyl” may include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and the like.
- Suitable “aroyl” may include benzoyl, toluoyl, naphthoyl and the like.
- Suitable “leaving group” may include hydroxy, reactive group derived from hydroxy and the like.
- Suitable “reactive group derived from hydroxy” may include acid residue and the like.
- Suitable “acid residue” may include halogen (e.g. fluoro, chloro, bromo, iodo) , acyloxy (e.g. acetoxy, tosyloxy, mesyloxy, etc.) and the like.
- halogen e.g. fluoro, chloro, bromo, iodo
- acyloxy e.g. acetoxy, tosyloxy, mesyloxy, etc.
- the object compound (I) or a salt thereof can be prepared by reacting a compound (II) or its reactive derivative at the carboxy group or a salt thereof with a compound (III) or its reactive derivative at the amino group or a salt thereof.
- Suitable reactive derivative at the carboxy group of the compound (II) may include an acid halide, an acid anhydride, an activated amide, an activated ester, and the like.
- Suitable examples of the reactive derivatives may be an acid chloride; an acid azide; a mixed acid anhydride with an acid such as substituted phosphoric acid [e.g. dialkylphosphoric acid, phenylphosphoric acid, diphenylphosphoric acid, dibenzylphosphoric acid, halogenated phosphoric acid, etc.], dialkylphosphorous acid, sulfurous acid, thiosulfuric acid, sulfuric acid, sulfonic acid [e.g. methanesulfonic acid, etc.], aliphatic carboxylic acid [e.g. acetic acid, propionic acid, butyric acid, isobutyric acid, pivalic acid, pentanoic acid, isopentanoic acid,
- substituted phosphoric acid e.g. dialkylphosphoric
- cvanomethyl ester methoxymethyl ester, dimethyliminomethyl [ ester, vinyl ester, propargyl ester, p-nitrophenyl ester, 2,4-dinitrophenyl ester, trichlorophenyl ester, pentachlorophenyl ester, mesylphenyl ester, phenylazophenyl ester, phenyl thioester, p-nitrophenyl thioester, p-cresyl thioester, carboxymethyl thioester, pyranyl ester, pyridyl ester, piperidyl ester, 8-quinolyl thioester, etc.], or an ester with a N-hydroxy compound [e.g.
- Suitable reactive derivative at the amino group of the compound (III) may include Schiff's base type imino or its tautomeric enamine type isomer formed by the reaction of the compound (III) with a carbonyl compound such as aldehyde, ketone or the like; a silyl derivative formed by the reaction of the compound (III) with a silyl compound such as bis (trimethylsilyl)acetamide, mono (trimethylsilyl) acetamide, bis (trimethylsilyl)urea or the like; a derivative formed by reaction of the compound (III) with phosphorus trichloride or phosgene and the like.
- the reaction is usually carried out in a conventional solvent such as water, alcohol [e.g. methanol, ethanol, etc.], acetone, 2-butanone, dioxane, acetonitrile, chloroform, methylene chloride, ethylene chloride, tetrahydrofuran, ethyl acetate, N,N-dimethylformamide, pyridine or any other organic solvent which does not adversely influence the reaction, or the mixture thereof.
- a conventional solvent such as water, alcohol [e.g. methanol, ethanol, etc.], acetone, 2-butanone, dioxane, acetonitrile, chloroform, methylene chloride, ethylene chloride, tetrahydrofuran, ethyl acetate, N,N-dimethylformamide, pyridine or any other organic solvent which does not adversely influence the reaction, or the mixture thereof.
- the reaction when the compound (II) is used in a free acid form or its salt form, the reaction is preferably carried out in the presence of a conventional condensing agent such as N,N'-dicyclohexylcarbodiimide; N-cyclohexyl-N'-morpholinoethylcarbodiimide; N-cyclohexyl-N'- (4-diethylaminocyclohexyl) carbodiimide; N,N'-diethylcarbodiimide; N,N'-diisopropylcarbodiimide; N-ethyl-N'- (3-dimethylaminopropyl)carbodiimide; pentamethyleneketene-N-cyclohexylimine; diphenylketene-N-cyclohexylimine; ethoxyacetylene; 1-alkoxy-l-chloroethylene; trialkyl phosphite; ethyl poly
- the reaction may also be carried out in the presence of an inorganic or organic base such as an alkali metal bicarbonate, tri (lower)alkylamine, pyridine, N-(lower) alkylmorpholine, N,N-di (lower)alkylbenzylamine, or the like.
- an inorganic or organic base such as an alkali metal bicarbonate, tri (lower)alkylamine, pyridine, N-(lower) alkylmorpholine, N,N-di (lower)alkylbenzylamine, or the like.
- the reaction temperature is not critical, and the reaction is usually carried out under cooling to warming.
- the object compound (If) can be prepared by reacting the compound (I) or a salt thereof other than fumaric acid salt thereof with fumaric acid.
- the reaction is usually carried out in a conventional solvent such as water, alcohol [e.g. methanol, ethanol, etc.], acetone, 2-butanone, dioxane, acetonitrile, chloroform, methylene chloride, ethylene chloride, tetrahydrofuran, ethyl acetate, N,N-dimethylformamide, pyridine or any other organic solvent which does not adversely influence the reaction, or the mixture thereof.
- a conventional solvent such as water, alcohol [e.g. methanol, ethanol, etc.], acetone, 2-butanone, dioxane, acetonitrile, chloroform, methylene chloride, ethylene chloride, tetrahydrofuran, ethyl acetate, N,N-dimethylformamide, pyridine or any other organic solvent which does not adversely influence the reaction, or the mixture thereof.
- the reaction temperature is not critical, and the reaction is usually carried out under cooling to warming.
- the object compound (Ig') or a salt thereof can be prepared by reacting the compound (IV) or its reactive derivative at the imino group or a salt thereof with the compound (V) or a salt thereof.
- Suitable reactive derivative at the imino group of the compound (IV) may include Schiff's base type imino or its tautomeric enamine type isomer formed by the reaction of the compound (IV) with a carbonyl compound such as aldehyde, ketone or the like; a silyl derivative formed by the reaction of the compound (IV) with a silyl compound such as bis (trimethylsilyl) acetamide, mono(trimethylsilyl)acetamide. bis (trimethylsilyl)urea or the like; a derivative formed by reaction of the compound (IV) with phosphorus trichloride or phosgene and the like.
- This reaction is usually carried out in a solvent such as alcohol [e.g. methanol, ethanol, etc.], dichloromethane, benzene, N,N-dimethylformamide, tetrahydrofuran, diethyl ether or any other solvent which does not adversely affect the reaction.
- a solvent such as alcohol [e.g. methanol, ethanol, etc.], dichloromethane, benzene, N,N-dimethylformamide, tetrahydrofuran, diethyl ether or any other solvent which does not adversely affect the reaction.
- the raction may be carried out in the presence of an inorganic or an organic base such as an alkali metal hydroxide [e.g. sodium hydroxide, potassium hydroxide, etc.], an alkali metal carbonate [e.g. sodium carbonate, potassium carbonate, etc.], an alkali metal bicarbonate [e.g. sodium bicarbonate, potassium bicarbonate, etc.], alkali metal hydride [e.g. sodium hydride, potassium hydride, etc.], tri (lower) alkylamine [e.g. trimethylamine, triethylamine, diisopropylethylamine, etc.], pyridine or its derivative [e.g. picoline, lutidine, 4-dimethylaminopyridine, etc.], or the like.
- an alkali metal hydroxide e.g. sodium hydroxide, potassium hydroxide, etc.
- an alkali metal carbonate e.g. sodium carbonate, potassium carbonate, etc.
- the reaction temperature is not critical, and the reaction can be carried out under cooling, at room temperature or under warming or heating.
- the compound (Ig") or a salt thereof can be prepared by reacting a compound (IV) or its reactive derivative at the imino group or a salt thereof with a compound (VI) or its reactive derivative at the carboxy group or a salt thereof.
- the reaction can be carried out in the manner disclosed in Preparation 10 or similar manners thereto.
- the object compounds of the present invention have pharmacological activities such as Tachykinin antagonism, especially Substance P antagonism, Neurokinin A antagonism or Neurokinin B antagonism, and therefore are useful for treating or preventing Tachykinin-mediated diseases, particularly Substance P-mediated diseases, for example, respiratory diseases such as asthma, bronchitis (e.g.
- ophthalmic diseases such as conjunctivitis, vernal conjunctivitis, and the like
- cutaneous diseases such as contact dermatitis, atopic dermatitis, urticaria, and other eczematoid dermatitis, and the like
- inflammatory diseases such as rheumatoid arthritis, osteoarthritis, and the like
- pains or aches e.g. migraine, headache, cluster headache, toothache, cancerous pain, back pain, neuralgia, etc.
- the object compounds of the present invention are useful for treating or preventing ophthalmic diseases such as glaucoma, uveitis, and the like; gastrointestinal diseases such as ulcer, ulcerative colitis, irritable bowel syndrome, food allergy, and the like; inflammatory diseases such as nephritis, and the like, circulatory diseases such as hypertension, angina pectoris, cardiac failure, thrombosis, Raynaud's disease, and the like; epilepsy; spastic paralysis; pollakiuria; cystitis; bladder detrusor hyperreflexia; urinary incontinence; Parkinson- diseases; dementia; AIDS related dementia; Alzheimer's diseases; Down's syndrome; Huntington's chorea; carcinoid syndrome; disorders related to immune enhancement or suppression; disorders caused by Helicobacter pylori or another spiral urease-positive gram-negative bacterium; sunburn; angiogenesis or diseases caused by angiogenesis; and the like.
- ophthalmic diseases such as glaucoma,
- the object compounds of the present invention are useful for treating or preventing chronic obstructive pulmonary diseases, particularly chronic pulmonary emphysema; blinkis; proliferative vitreoretinopathy; psoriasis; inflammatory intestinal diseases, particularly Crohn's diseases; hepatitis; superficial pain on congelation, burn, herpes zoster or diabetic neuropathy; tenalgia attended to hyperlipidemia; postoperative neuroma, particularly of mastectomy; vulvar vestibulitis; he odialysis-associated itching; lichen planus; laryngopharyngitis; bronchiectasis; coniosis; whooping cough; pulmonary tuberculosis; cystic fibrosis; e esis; mental diseases, particularly anxiety, depression, dysthymic disorders and schizophrenia; demyelinating diseases such as multiple sclerosis and amyotrophic lateral sclerosis; attenuation of morphine withdrawal; oe
- the object compounds of the present invention can be used in a form of pharmaceutical preparation containing one of said compound, as an active ingredient, in admixture with a pharmaceutically acceptable carrier such as an organic or inorganic solid or liquid excipient suitable for oral, parenteral, external including topical, enteral, intravenous, intramuscular, inhalant, nasal, intraarticular, intraspinal, transtracheal or transocular administration.
- a pharmaceutically acceptable carrier such as an organic or inorganic solid or liquid excipient suitable for oral, parenteral, external including topical, enteral, intravenous, intramuscular, inhalant, nasal, intraarticular, intraspinal, transtracheal or transocular administration.
- the pharmaceutical preparations may be solid, semi-solid or solutions such as capsules, tablets, pellets, dragees, powders, granules, suppositories, ointments, creams, lotions, inhalants, injections, cataplasms, gels, tapes, eye drops, solution, syrups, aerosols, suspension, emulsion, or the like.
- auxiliary substances stabilizing agents, wetting or emulsifying agents, buffers and other commonly used additives.
- an average single dose of about 0.1 mg, 1 mg, 10 mg, 50 mg, 100 mg, 250 mg, 500 mg and 1000 mg of the object compounds may be effective for treating Tachykinin-mediated diseases such as asthma and the like.
- amounts between 0.1 mg/body and about 1,000 mg/body may be administered per day.
- CHO cells permanently expressing h-NK-, receptors were harvested and homogenized with a Dounce homogenizer at 4°C in a buffer (0.25 M sucrose, 25 M Tris-HCl pH 7.4, 10 mM MgCl 2 ,
- Cell membranes (6 ⁇ g/ml) were incubated with 12 ⁇ I-BH- Substance P (0.1 nM) with or without test compounds in 0.25 ml of Medium 2 (50 mM Tris-HCl pH 7.4, 5 mM MnCl 2 , 20 ⁇ g/ml chvmostatin, 40 ⁇ g/ml bacitracin, 4 ⁇ g/ml leupeptin, 5 ⁇ g/ml p-APMSF, 200 ⁇ g/ml BSA) at 22°C for 90 minutes. At the end of the incubation period, the content was quickly filtered over a Wahtman GF/C glass filter (pretreated with 0.1% polyethylene imine for 3 hours prior to use) under aspiration.
- Medium 2 50 mM Tris-HCl pH 7.4, 5 mM MnCl 2 , 20 ⁇ g/ml chvmostatin, 40 ⁇ g/ml bacitracin, 4 ⁇ g/ml le
- the object compound of the present invention is also superior in stability and the like.
- Example 5 The following piperazine derivatives (Table 1) were prepared by the similar manner to that of the each Example
Abstract
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US45017695A | 1995-05-25 | 1995-05-25 | |
US450176 | 1995-05-25 | ||
PCT/JP1996/001335 WO1996037489A1 (fr) | 1995-05-25 | 1996-05-21 | Derives de 1-benzoyl-2-(indolyl-3-alkyl)-piperazine utilises comme antagonistes du recepteur de la neurokinine |
Publications (1)
Publication Number | Publication Date |
---|---|
EP0846116A1 true EP0846116A1 (fr) | 1998-06-10 |
Family
ID=23787083
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP96915200A Ceased EP0846116A1 (fr) | 1995-05-25 | 1996-05-21 | Derives de 1-benzoyl-2-(indolyl-3-alkyl)-piperazine utilises comme antagonistes du recepteur de la neurokinine |
Country Status (14)
Country | Link |
---|---|
EP (1) | EP0846116A1 (fr) |
JP (1) | JP3071829B2 (fr) |
KR (1) | KR19990021857A (fr) |
CN (1) | CN1072220C (fr) |
AU (1) | AU706021B2 (fr) |
CA (1) | CA2222041A1 (fr) |
EA (1) | EA000669B1 (fr) |
HU (1) | HUP9900822A3 (fr) |
IL (1) | IL118369A (fr) |
NZ (1) | NZ307625A (fr) |
TR (1) | TR199600438A2 (fr) |
TW (1) | TW391960B (fr) |
WO (1) | WO1996037489A1 (fr) |
ZA (1) | ZA964101B (fr) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2189501A1 (fr) * | 1995-11-06 | 1997-05-07 | Harry R. Howard | Antagonistes des recepteurs de nk-1 pour le traitement du cancer |
US6087357A (en) * | 1995-12-18 | 2000-07-11 | Fujisawa Pharmaceutical Co., Ltd. | Piperazine derivatives as tachykinin antagonists |
AUPO735997A0 (en) | 1997-06-17 | 1997-07-10 | Fujisawa Pharmaceutical Co., Ltd. | Piperazine derivatives |
DE19824865A1 (de) * | 1997-08-27 | 1999-03-04 | Solvay Pharm Gmbh | Neue Harnstoffderivate |
DE59814233D1 (de) * | 1997-08-27 | 2008-07-03 | Solvay Pharm Gmbh | Indolmethyl-N,N'-bisacylpiperazine als Neurokininrezeptorantagonisten |
US6833373B1 (en) | 1998-12-23 | 2004-12-21 | G.D. Searle & Co. | Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia |
DE10036818A1 (de) * | 2000-07-28 | 2002-02-07 | Solvay Pharm Gmbh | Neue N-Triazolylmethyl-Piperazinderivate als Neurokininrezeptor-Antagonisten |
UA75425C2 (en) * | 2001-07-09 | 2006-04-17 | Piperazine oxime derivatives with antagonistic activity to nk-1 receptor, use thereof, a pharmaceutical composition based thereon, a method for producing and a method for producing intermediary compounds | |
UA77515C2 (en) | 2002-04-04 | 2006-12-15 | Diazabicyclo alkane derivatives possessing neuroldnin-nk1 receptor antagonistic activity | |
KR101389246B1 (ko) | 2004-07-15 | 2014-04-24 | 브리스톨-마이어스스퀴브컴파니 | 아릴- 및 헤테로아릴-치환된 테트라히드로이소퀴놀린, 및 이것의 노르에피네프린, 도파민 및 세로토닌의 재흡수를 차단하기 위한 용도 |
US8362075B2 (en) | 2005-05-17 | 2013-01-29 | Merck Sharp & Dohme Corp. | Cyclohexyl sulphones for treatment of cancer |
JP5258561B2 (ja) | 2005-07-15 | 2013-08-07 | アルバニー モレキュラー リサーチ, インコーポレイテッド | アリール置換およびヘテロアリール置換テトラヒドロベンズアゼピンならびにノルエピネフリン、ドーパミンおよびセロトニンの再取り込みを遮断するためのその使用 |
JP4879988B2 (ja) | 2005-09-29 | 2012-02-22 | メルク・シャープ・エンド・ドーム・コーポレイション | メラノコルチン−4受容体モジュレーターとしてのアシル化スピロピペリジン誘導体 |
GB0603041D0 (en) | 2006-02-15 | 2006-03-29 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
WO2008039327A2 (fr) | 2006-09-22 | 2008-04-03 | Merck & Co., Inc. | Procédé de traitement utilisant des inhibiteurs de synthèse d'acide gras |
US20110218176A1 (en) | 2006-11-01 | 2011-09-08 | Barbara Brooke Jennings-Spring | Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development |
CA2674436C (fr) | 2007-01-10 | 2012-07-17 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Indazoles a substitution amide utilises comme inhibiteurs de la poly(adp-ribose)polymerase (parp) |
CA2676357A1 (fr) | 2007-01-24 | 2008-07-31 | Glaxo Group Limited | Nouvelles compositions pharmaceutiques |
EP2145884B1 (fr) | 2007-04-02 | 2014-08-06 | Msd K.K. | Dérivé d'indoledione |
WO2008147864A2 (fr) * | 2007-05-22 | 2008-12-04 | Xenon Pharmaceuticals Inc. | Procédés d'utilisaton de composés pipérazine dans le traitement de maladies ou états médiés par le canal sodium |
CA2690191C (fr) | 2007-06-27 | 2015-07-28 | Merck Sharp & Dohme Corp. | Derives de 4-carboxybenzylamino utilises en tant qu'inhibiteurs de l'histone desacetylase |
KR20100126467A (ko) | 2008-03-03 | 2010-12-01 | 타이거 파마테크 | 티로신 키나아제 억제제 |
US9156812B2 (en) | 2008-06-04 | 2015-10-13 | Bristol-Myers Squibb Company | Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine |
US8691825B2 (en) | 2009-04-01 | 2014-04-08 | Merck Sharp & Dohme Corp. | Inhibitors of AKT activity |
EP2429296B1 (fr) | 2009-05-12 | 2017-12-27 | Albany Molecular Research, Inc. | 7-([1,2, 4,]triazolo[1,5,-a]pyridine-6-yl)-4-(3,4-dichlorophényl)-1,2,3,4- tétrahydroisoquinoline et son utilisation |
MX2011011901A (es) | 2009-05-12 | 2012-01-20 | Albany Molecular Res Inc | Tetrahidroisoquinolinas aril, heteroaril, y heterociclo sustituidas y uso de las mismas. |
JP5739415B2 (ja) | 2009-05-12 | 2015-06-24 | ブリストル−マイヤーズ スクウィブ カンパニー | (S)−7−([1,2,4]トリアゾロ[1,5−a]ピリジン−6−イル)−4−(3,4−ジクロロフェニル)−1,2,3,4−テトラヒドロイソキノリンの結晶形態およびその使用 |
EA023838B1 (ru) | 2009-10-14 | 2016-07-29 | Мерк Шарп Энд Домэ Корп. | ЗАМЕЩЕННЫЕ ПИПЕРИДИНЫ, КОТОРЫЕ ПОВЫШАЮТ АКТИВНОСТЬ p53, И ИХ ПРИМЕНЕНИЕ |
WO2011163330A1 (fr) | 2010-06-24 | 2011-12-29 | Merck Sharp & Dohme Corp. | Nouveaux composés hétérocycliques utilisés comme inhibiteurs de erk |
EP3330377A1 (fr) | 2010-08-02 | 2018-06-06 | Sirna Therapeutics, Inc. | Inhibition à médiation par interférence arn de caténine (protéine associée à cadhérine), expression du gène bêta 1 (ctnnb1) à l'aide de petit acide nucléique interférent (sian) |
CA2807307C (fr) | 2010-08-17 | 2021-02-09 | Merck Sharp & Dohme Corp. | Inhibition mediee par des arn interferents de l'expression genique du virus de l'hepatite b (vhb) a l'aide de petits acides nucleiques interferents (pani) |
US8883801B2 (en) | 2010-08-23 | 2014-11-11 | Merck Sharp & Dohme Corp. | Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors |
EP2613782B1 (fr) | 2010-09-01 | 2016-11-02 | Merck Sharp & Dohme Corp. | Dérivés d'indazole utilisables en tant qu'inhibiteurs de la voie erk |
WO2012036997A1 (fr) | 2010-09-16 | 2012-03-22 | Schering Corporation | Dérivés condensés de pyrazole utilisés comme nouveaux inhibiteurs erk |
EP3766975A1 (fr) | 2010-10-29 | 2021-01-20 | Sirna Therapeutics, Inc. | Inhibition au moyen d'interférence arn d'une expression de gène utilisant des acides nucléiques à petit interférent (sina) |
US9351965B2 (en) | 2010-12-21 | 2016-05-31 | Merck Sharp & Dohme Corp. | Indazole derivatives useful as ERK inhibitors |
CN103732592A (zh) | 2011-04-21 | 2014-04-16 | 默沙东公司 | 胰岛素样生长因子-1受体抑制剂 |
US9023865B2 (en) | 2011-10-27 | 2015-05-05 | Merck Sharp & Dohme Corp. | Compounds that are ERK inhibitors |
EP2844261B1 (fr) | 2012-05-02 | 2018-10-17 | Sirna Therapeutics, Inc. | Compositions de petit acide nucléique interférent (sina) |
US9233979B2 (en) | 2012-09-28 | 2016-01-12 | Merck Sharp & Dohme Corp. | Compounds that are ERK inhibitors |
SI2925888T1 (en) | 2012-11-28 | 2018-02-28 | Merck Sharp & Dohme Corp. | Compounds and methods for the treatment of cancer |
AU2013361694B2 (en) | 2012-12-20 | 2017-10-26 | Merck Sharp & Dohme Corp. | Substituted imidazopyridines as HDM2 inhibitors |
EP2951180B1 (fr) | 2013-01-30 | 2018-05-02 | Merck Sharp & Dohme Corp. | Purines 2,6,7,8-substituées utilisées en tant qu'inhibiteurs de hdm2 |
US20160194368A1 (en) | 2013-09-03 | 2016-07-07 | Moderna Therapeutics, Inc. | Circular polynucleotides |
WO2019094311A1 (fr) | 2017-11-08 | 2019-05-16 | Merck Sharp & Dohme Corp. | Inhibiteurs de prmt5 |
WO2020033284A1 (fr) | 2018-08-07 | 2020-02-13 | Merck Sharp & Dohme Corp. | Inhibiteurs de prmt5 |
WO2020033282A1 (fr) | 2018-08-07 | 2020-02-13 | Merck Sharp & Dohme Corp. | Inhibiteurs de prmt5 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK0411150T3 (da) * | 1989-02-10 | 1996-12-16 | Otsuka Pharma Co Ltd | Indolderivater |
IL111730A (en) * | 1993-11-29 | 1998-12-06 | Fujisawa Pharmaceutical Co | Piperazine derivatives, processes for their preparation and pharmaceutical preparations containing them |
-
1996
- 1996-05-21 CA CA002222041A patent/CA2222041A1/fr not_active Abandoned
- 1996-05-21 EA EA199700425A patent/EA000669B1/ru not_active IP Right Cessation
- 1996-05-21 CN CN96195744A patent/CN1072220C/zh not_active Expired - Fee Related
- 1996-05-21 KR KR1019970708331A patent/KR19990021857A/ko not_active Application Discontinuation
- 1996-05-21 NZ NZ307625A patent/NZ307625A/xx unknown
- 1996-05-21 EP EP96915200A patent/EP0846116A1/fr not_active Ceased
- 1996-05-21 AU AU57031/96A patent/AU706021B2/en not_active Ceased
- 1996-05-21 JP JP8535553A patent/JP3071829B2/ja not_active Expired - Fee Related
- 1996-05-21 WO PCT/JP1996/001335 patent/WO1996037489A1/fr not_active Application Discontinuation
- 1996-05-21 HU HU9900822A patent/HUP9900822A3/hu unknown
- 1996-05-22 IL IL11836996A patent/IL118369A/xx active IP Right Grant
- 1996-05-22 ZA ZA964101A patent/ZA964101B/xx unknown
- 1996-05-23 TW TW085106105A patent/TW391960B/zh not_active IP Right Cessation
- 1996-05-24 TR TR96/00438A patent/TR199600438A2/xx unknown
Non-Patent Citations (1)
Title |
---|
See references of WO9637489A1 * |
Also Published As
Publication number | Publication date |
---|---|
HUP9900822A2 (hu) | 1999-06-28 |
EA000669B1 (ru) | 2000-02-28 |
IL118369A (en) | 2000-06-01 |
JPH11505830A (ja) | 1999-05-25 |
CN1191533A (zh) | 1998-08-26 |
AU706021B2 (en) | 1999-06-03 |
TW391960B (en) | 2000-06-01 |
IL118369A0 (en) | 1996-09-12 |
TR199600438A2 (tr) | 1996-12-21 |
NZ307625A (en) | 1999-02-25 |
CN1072220C (zh) | 2001-10-03 |
EA199700425A1 (ru) | 1998-12-24 |
AU5703196A (en) | 1996-12-11 |
WO1996037489A1 (fr) | 1996-11-28 |
JP3071829B2 (ja) | 2000-07-31 |
CA2222041A1 (fr) | 1996-11-28 |
ZA964101B (en) | 1996-07-29 |
HUP9900822A3 (en) | 1999-11-29 |
KR19990021857A (ko) | 1999-03-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0846116A1 (fr) | Derives de 1-benzoyl-2-(indolyl-3-alkyl)-piperazine utilises comme antagonistes du recepteur de la neurokinine | |
EP0655442B1 (fr) | Dérivés de pipérazine en tant qu'antagonistes de Tachykinine | |
US6087357A (en) | Piperazine derivatives as tachykinin antagonists | |
RU2258702C2 (ru) | Производные ароилпиперазина, способ их получения, фармацевтическая композиция на их основе и способ лечения | |
EP0640099A1 (fr) | Peptides ayant une action antagoniste de la tachykinine | |
CA2033363A1 (fr) | Derives de la quinazoline et leur preparation | |
US5939413A (en) | Piperazine derivatives | |
US5883098A (en) | Piperazine derivatives | |
US5654400A (en) | Process for making peptide compounds having tachykinin antagonistic activity | |
MXPA97009079A (en) | Derivatives of 1-benzol-2- (indolil-3-alkyl) piperazine as antagonists of the neuroquin receiver | |
AU743723B2 (en) | Aroyl-piperazine derivatives, their preparation and their use as tachykinin antagonists | |
MXPA98004887A (en) | Piperazine derivatives as taquicin antagonists | |
MXPA99011778A (en) | Aroyl-piperazine derivatives, their preparation and their use as tachykinin antagonists |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19971128 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE |
|
17Q | First examination report despatched |
Effective date: 20010219 |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED |
|
18R | Application refused |
Effective date: 20021102 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1008990 Country of ref document: HK |